Stock Report

All about this stock under one free report Last Updated: 28-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Jenburkt Pharma Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

BSE: 524731

₹948.00

up-down-arrow ₹-6.00 (-0.63%)

As on 25-Sep-2026IST

Market cap

info icon

₹419 Cr

Revenue (TTM)

info icon

₹169 Cr

P/E Ratio

info icon

12.7

P/B Ratio

info icon

2.1

Div. Yield

info icon

2.2 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -20.43 -0.04 9.08 7.77 7.22
EBIT -59.93 -34.60 1.76 10.72 10.83
Net Profit -57.90 -24.48 10.84 14.39 12.28
EPS -45.76 -24.48 1.20 11.67 11.13
Book Value -- -- 14.71 17.20 15.78
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 23.5322.3222.3924.0824.83
Net Margin info 19.1218.4018.3919.4020.24
Return on equity info 19.5119.9418.9318.8420.25
Return on Capital info 26.4926.63--25.3427.85
Return on Assets info 17.1517.1515.5516.6117.86
Debt to Equity (x) info ----0.000.000.01

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
--
25.34
27.85
26.28
26.80
Peer Median
--
14.77
14.72
18.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

18.93

Higher than Peers by 8.07

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
18.93
18.84
20.25
19.43
20.53
Peer Median
10.86
12.35
11.67
14.92
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

15.55

Higher than Peers by 8.81

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
15.55
16.61
17.86
17.00
17.33
Peer Median
6.74
6.87
7.86
9.06
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

22.39

Higher than Peers by 9.70

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
22.39
24.08
24.83
21.68
20.55
Peer Median
12.69
14.78
15.03
14.71
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

18.39

Higher than Peers by 9.53

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
18.39
19.40
20.24
17.72
17.34
Peer Median
8.86
8.30
9.33
8.49
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
0.00
22.43
22.93
19.95
19.65
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

9.08

Higher than Peers by 0.94

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
9.08
11.24
6.85
3.82
10.30
Peer Median
8.14
14.12
10.27
11.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

1.76

Lower than Peers by 15.49

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
1.76
7.88
22.37
9.50
10.85
Peer Median
17.24
21.59
24.15
28.00
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

10.84

Lower than Peers by 6.01

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
10.84
8.34
23.42
5.57
10.36
Peer Median
16.85
28.31
30.29
36.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

1.20

Lower than Peers by 9.40

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
1.20
8.34
23.42
5.57
14.76
Peer Median
10.60
14.25
24.50
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
--
14.71
18.52
18.43
4.27
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
--
--
0.01
--
0.02
Peer Median
0.04
0.22
0.23
0.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
--
--
0.01
--
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

4.11

Higher than Peers by 2.39

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
4.11
4.11
3.00
6.70
5.14
Peer Median
1.72
1.82
1.79
1.96
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.52

Higher than Peers by 2.34

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
3.52
3.52
2.53
6.18
4.62
Peer Median
1.17
1.23
1.47
1.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

90.43

Higher than Peers by 82.57

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
90.43
101.69
98.02
130.99
90.55
Peer Median
7.86
7.86
9.42
8.58
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

14.44

Lower than Peers by 11.35

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
14.44
14.43
13.67
13.72
12.40
Peer Median
25.79
25.29
25.82
26.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.80

Higher than Peers by 0.13

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
0.80
0.81
0.85
0.93
0.96
Peer Median
0.67
0.73
0.75
0.77
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
--
48.77
48.38
46.84
42.93
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
--
24.35
20.98
21.72
24.32
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
--
106.30
101.38
84.76
84.44
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
--
-33.18
-32.02
-16.20
-17.19
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

12.75

Lower than Peers by 35.84

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
12.75
12.14
13.93
11.71
11.94
Peer Median
48.59
48.59
39.70
33.48
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

2.06

Lower than Peers by 2.79

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
2.06
2.14
2.60
2.10
2.40
Peer Median
4.85
5.15
3.72
4.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

2.18

Higher than Peers by 2.08

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
2.18
2.17
1.78
2.22
2.16
Peer Median
0.10
0.10
0.16
0.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

7.23

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
7.23
6.82
9.00
5.96
6.83
Peer Median
--
34.11
30.23
29.90
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

419

Lower than Peers by 8,096

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jenburkt Pharma
419
422
446
304
294
Peer Median
8,514
6,789
4,851
2,099
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...